These results demonstrate that shRNA therapy against TβR1 as well as its combination with bosentan significantly alleviate the pathological process of hepatic fibrosis, and the associated pathological changes are adequately reflected by the ARFI values. This evidence concerns the gene TBR1 and Hepatic fibrosis.